Literature DB >> 1856950

The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer.

P M van der Meijden1, B van Klingeren, P A Steerenberg, L C de Boer, W H de Jong, F M Debruyne.   

Abstract

Intravesical treatment with Bacillus Calmette-Guérin is an established treatment of carcinoma in situ and an effective prophylaxis for the prevention of recurrence of transitional cell carcinoma. During instillation therapy oral antibiotics may be used to prevent or to treat urinary tract infections. Tuberculostatic agents are employed to prevent or to treat local irritative symptoms and systemic side effects caused by Bacillus Calmette-Guérin. We investigated the susceptibility of four different Bacillus Calmette-Guérin preparations to 18 antibiotics and to 11 tuberculostatic agents in vitro. All preparations were equally susceptible to most of the commonly used antibiotics and to all of the tuberculostatic agents with the exception of pyrazinamide. Our results suggest that in the absence of cystitis, instillations should not be accompanied by antibiotics because of the possible inhibition of antitumor efficacy by eradication of living Bacillus Calmette-Guérin organisms. The same inhibition may occur when tuberculostatic agents are used to prevent local and systemic complications of Bacillus Calmette-Guérin instillation therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856950     DOI: 10.1016/s0022-5347(17)37821-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Immune responses of patients without cancer recurrence after a cancer vaccine over a long term.

Authors:  Shigetaka Suekane; Shigeru Yutani; Uhi Toh; Koichi Yoshiyama; Kyogo Itoh
Journal:  Mol Clin Oncol       Date:  2022-05-13

2.  Intravesical treatment of severe bacillus Calmette-Guerin cystitis.

Authors:  J Palou; L Rodríguez-Villamil; A Andreu-Crespo; J Salvador-Bayarri; J Vicente-Rodríguez
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

3.  Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients.

Authors:  P Conti; M Reale; M Nicolai; R C Barbacane; F C Placido; R Iantorno; R Tenaglia
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

Review 4.  Superficial bladder cancer.

Authors:  R R Hall
Journal:  BMJ       Date:  1994-04-02

5.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

6.  Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer.

Authors:  Sahyun Pak; Sun-Young Kim; Sung Han Kim; Jae Young Joung; Weon Seo Park; Jinsoo Chung; Kang Hyun Lee; Ho Kyung Seo
Journal:  Front Oncol       Date:  2021-04-02       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.